DENTSPLY SIRONA (NASDAQ:XRAY) Stock Gets Price Target Trim from Barrington Research

DENTSPLY SIRONA (NASDAQ:XRAY) had its price target lowered by Barrington Research from $15.00 to $13.00 in a research report report published on Monday, MarketBeat Ratings reports. The firm currently has an outperform rating on the medical instruments supplier’s stock.

Several other equities analysts have also issued reports on the company. Mizuho reduced their target price on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, October 22nd. BMO Capital Markets decreased their price target on DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating for the company in a research report on Thursday, September 17th. Piper Sandler dropped their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Friday, October 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. Finally, Barclays boosted their price objective on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research report on Monday, August 24th. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $12.62.

DENTSPLY SIRONA Stock Up 1.0%

DENTSPLY SIRONA stock opened at $9.44 on Monday. DENTSPLY SIRONA has a fifty-two week low of $8.32 and a fifty-two week high of $14.76. The stock has a market cap of $1.88 billion, a PE ratio of -3.43, a price-to-earnings-growth ratio of 1.20 and a beta of 0.87. The firm’s 50-day simple moving average is $9.75 and its 200 day simple moving average is $11.37. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. The business had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The firm’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts predict that DENTSPLY SIRONA will post 1.39 EPS for the current fiscal year.

Institutional Trading of DENTSPLY SIRONA

Several hedge funds have recently added to or reduced their stakes in XRAY. BlackRock Inc. purchased a new position in DENTSPLY SIRONA in the second quarter valued at about $283,405,000. Southpoint Capital Advisors LP bought a new position in shares of DENTSPLY SIRONA during the 1st quarter valued at approximately $116,000,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of DENTSPLY SIRONA during the 2nd quarter worth approximately $47,780,000. Dimensional Fund Advisors LP increased its stake in shares of DENTSPLY SIRONA by 31.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,559,388 shares of the medical instruments supplier’s stock worth $41,284,000 after purchasing an additional 850,261 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY purchased a new stake in shares of DENTSPLY SIRONA during the 2nd quarter worth approximately $39,775,000. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.